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STATE OF THE ART: CONCISE REVIEW
Targeting Angiogenesis in the Treatment of Lung Cancer
Paul Wheatley-Price, MBChB, MRCP, and Frances A. Shepherd, MD, FRCPC
Abstract: Inhibition of angiogenesis now plays a central role in the
management of many malignancies. Angiogenesis plays an impor-
tant role in lung cancer and increasing numbers of antiangiogenesis
agents are being investigated in all types of pulmonary malignan-
cies. The monoclonal antibody, bevacizumab, has demonstrated
efficacy (improved response rates and overall survival) in phase II
and III trials in combination with standard first-line chemotherapy in
non-small cell lung cancer. However patients in the large phase III
studies were highly selected to reduce the risk of fatal hemoptysis.
Many small molecule tyrosine kinase inhibitors, particularly sor-
afenib, sunitinib, vandetanib, and cediranib, are currently being
investigated in phase III trials as monotherapy or in combination
with standard therapy. Alternative antiangiogenesis approaches such
as vascular endothelial growth factor-trap and anticoagulation are
also being investigated. Targeting angiogenesis is an exciting and
attractive area in the treatment of lung cancer, and the results of
ongoing trials are eagerly awaited. More work is required to identify
subgroups of patients most likely to benefit from these drugs.
Key Words: Non-small cell lung cancer, Small-cell lung cancer,
Angiogenesis.
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Lung cancer is the most common cause of cancer mortalityworldwide, with over one million deaths each year.1
The majority of patients present with incurable disease,
and platinum-based chemotherapy may improve both quantity
and quality of life; however, median survival remains less
than 1 year.2,3
For tumors to grow more than a few millimeters in
diameter they must establish a new blood supply.4 The
“angiogenic switch” required to develop new vessels occurs
when pro-angiogenic stimuli for new vessel formation (in-
cluding tumor-secreted cytokines), become dominant over
naturally occurring angiogenesis inhibitors.5
The most common angiogenic cytokines are the
vascular endothelial growth factor (VEGF) family of li-
gands, consisting of six members (VEGF-A, VEGF-B,
VEGF-C, VEGF-D, VEGF-E, and placental growth factor)
that bind to one of three transmembrane receptors (VEGFR-1,
VEGFR-2, VEGFR-3).6 Other angiogenesis-mediating cyto-
kines include fibroblast growth factor, hepatocyte growth factor,
transforming growth factors- and , platelet-derived growth
factor (PDGF), tumor necrosis factor-, and interleukin-8.7,8 As
tumors grow their microenvironment becomes hypoxic, and
hypoxia-inducible factor (HIF) is activated. HIF up-regulation in
turn promotes transcription of pro-angiogenic cytokines includ-
ing VEGF.9 Once VEGF binds to its receptors, tyrosine kinase
activation occurs in the intracellular domain resulting in down-
stream signaling cascades, leading to endothelial cell activation,
migration and proliferation, and ultimately new vessel forma-
tion10 (Figure 1).
VEGF expression has been demonstrated in 42 to 75% of
non-small cell lung cancer (NSCLC) cases.11–17 Although
some studies have shown no correlation,13,17 many have
demonstrated an association between tumoral VEGF ex-
pression, more advanced disease, and a worse progno-
sis.11,12,15,18–21 In resected NSCLC, HIF-1 expression has
been demonstrated to be higher in areas of moderate and
severe tumor necrosis relative to areas of minimal necro-
sis.22 Microvessel density, a reflection of the process of
angiogenesis, is also predictive of metastases and poor
prognosis in NSCLC.23,24 Although fewer studies have
been reported, VEGF expression and high microvessel
density are also predictive of poor outcomes in small-cell
lung cancer (SCLC).25,26 Elevated pretreatment serum
VEFG levels are also associated with a poor response to
treatment and worse survival.27
Recently, many drugs have been developed that target
angiogenesis. This article reviews antiangiogenesis drugs
currently in clinical practice and in development for the
treatment of lung cancer. Table 1 summarizes these agents
and their targets. Table 2 lists the results of lung cancer trials
with antiangiogenesis used as monotherapy. Table 3 reviews
important ongoing phase III trials (www.clinicaltrials.gov).
Antibodies
Bevacizumab
Bevacizumab (Avastin, Genentech Inc., South San
Francisco, CA), a monoclonal antibody that targets VEGF,
initially entered clinical practice after demonstrating efficacy
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in metastatic colorectal cancer when used in combination
with chemotherapy.28
In the treatment of NSCLC, a randomized phase II
study compared carboplatin/paclitaxel alone or with bevaci-
zumab (7.5 or 15 mg/kg). The median time to progression
was longer in the group receiving bevacizumab 15 mg/kg
(7.4 versus 4.2 months), but the trial was complicated by a
high incidence of pulmonary hemorrhage (fatal in four
cases), that seemed to be associated mainly with squamous
cell histology.29 Therefore, in the subsequent phase III
Eastern Cooperative Oncology Group (ECOG) E4599 trial,
patients with squamous cell histology and those with a
history of hemoptysis were excluded. In this study, 878
patients were randomized to receive paclitaxel/carboplatin
chemotherapy alone (n  444) or chemotherapy plus
bevacizumab 15 mg/kg (n  434).30 Patients receiving
bevacizumab had a significantly higher response rate (35%
versus 15%, p  0.001) and also a significant survival
advantage (median 12.3 versus 10.3 months, p  0.003)
(Figure 2). In subgroup analysis this benefit was seen in
men (hazard ratio 0.70, 95% confidence interval 0.57–
0.87) but not in women (hazard ratio 0.98, 95% confidence
interval 0.77–1.25). The reason for this is unclear, but may
be explained by more women receiving second-line che-
motherapy in the chemotherapy alone group, although
there was no difference in the subsequent use of epidermal
growth factor receptor (EGFR) inhibitors. There was a
higher incidence of liver metastases in women receiving
bevacizumab, but this alone could not explain the observed
sex differences.31 Seven percent of patients in the bevaci-
zumab arm developed grade 3 or 4 hypertension (p 
0.001). There were five deaths from pulmonary hemor-
rhage in the bevacizumab arm and none in the control
group, and a subsequent analysis of the phase II and III
trials identified a history of hemoptysis or tumor cavitation
as significant risk factors for this toxicity.32,33 As a result
of this trial, bevacizumab/carboplatin/paclitaxel received
approval for the first-line treatment of advanced NSCLC in
the United States.34 A second large phase III trial
(AVAiL), comparing cisplatin/gemcitabine alone or in
combination with bevacizumab (7.5 or 15 mg/kg), has
reported provisional results. These show a statistically
significant improvement in response rates (30% versus
34% versus 20% in the 15 mg/kg, 7.5 mg/kg and placebo
arms, respectively) and progression free survival (PFS)
(6.5 versus 6.7 versus 6.1 month) in the bevacizumab
containing arms, supporting the results of E4599.35 Grade
3 or 4 hypertension was higher in the bevacizumab arms
(6–9%), but in contrast to the E4599 trial there was no
evidence of differential benefit between sexes. A subse-
quent press release has reported that AVAiL did not
demonstrate a significant overall survival (OS) benefit, a
secondary end point, in the bevacizumab cohort.36 Al-
though full results are still not available, these findings
contrast with those of E4599 and call into question the
degree of benefit patients will gain from the addition of
bevacizumab to standard chemotherapy.
Dual blockade of VEGF and the EGFR has been
suggested as potentially synergistic, with preclinical evi-
dence demonstrating increased inhibition after combining
antiangiogenesis and anti-EGFR drugs in mouse xenograft
models.37,38 The combination of bevacizumab and the EGFR
inhibitor erlotinib (Tarceva, OSI Pharmaceuticals, Melville,
NY) has shown efficacy in previously treated patients with
NSCLC.39 A phase II trial, comparing bevacizumab plus
docetaxel or pemetrexed versus bevacizumab plus erlotinib
versus docetaxel or pemetrexed plus placebo, reported a trend
toward improved survival in the bevacizumab-containing
cohorts, and lower toxicity in the bevacizumab/erlotinib
arm.40 The confirmatory phase III BeTa lung trial randomizes
previously treated NSCLC patients to erlotinib plus bevaci-
zumab versus erlotinib alone and remains open to accrual.
The phase III ATLAS trial is investigating bevacizumab with
or without erlotinib as maintenance treatment after comple-
tion of first-line chemotherapy in advanced disease.
FIGURE 1. Mechanisms of targeting angiogene-
sis. VEGF, vascular endothelial growth factor.
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Ongoing phase II trials are investigating bevacizumab
with different chemotherapy combinations regimens, such as
oxaliplatin/pemetrexed,41,42 nab-paclitaxel/carboplatin,43 pem-
etrexed/carboplatin,44 docetaxel/carboplatin,45 gemcitabine/car-
boplatin,46 or gemcitabine/oxaliplatin.47 Further trials of note
that currently are accruing include a phase II study combining
bevacizumab with chemotherapy and the EGFR monoclonal
antibody cetuximab (Erbitux, ImClone Systems Inc., New
York, NY) and a large phase III study of postoperative
chemotherapy with or without bevacizumab in resected stage
IB–IIIA NSCLC (ECOG E1505). This latter study includes
patients with squamous cell histology.
Bevacizumab has also been tested in combination
with chemotherapy in a number of single-arm phase II
trials in SCLC,48–51 although full efficacy data are not yet
available. The phase II SALUTE study (NCT00403403) is
randomizing patients with untreated extensive stage SCLC
to chemotherapy plus bevacizumab or placebo; however,
there are currently no active phase III studies in this group
of patients.
IMC-1121B
IMC-1121B (ImClone Systems Inc.) is a fully human-
ized monoclonal antibody that blocks binding of the VEGF
ligand to the extracellular domain of VEGFR-2. A phase I
trial in patients with advanced solid malignancies has re-
ported provisional results while dose escalation continues.
The drug was well tolerated with a partial response observed
in a single patient with melanoma.52 No lung cancer patients
have been enrolled.
IMC-18F1
IMC-18F1 (ImClone Systems Inc.) is a humanized
monoclonal antibody against VEGFR-1 that has demon-
strated antitumor activity in human breast cancer cell lines,
but currently there are no clinical trials of this agent.53
VEGF-Trap
Aflibercept
Aflibercept (VEGF-trap/AVE0005, Regeneron Phar-
maceuticals, Tarrytown, NY) is a fully human soluble
TABLE 1. Antiangiogenesis Inhibitors in Development and
in Practice
Drug Name Target
Stage of
Development
Bevacizumab VEGF Phase III
IMC-1121b VEGFR-2 Phase I
IMC-18F1 VEGFR-1 Preclinical
Aflibercept VEGF-A, PlGF Phase III
Sorafenib B-RAF, C-RAF, VEGFR2,
VEGFR3, PDGFR-, Kit
Phase III
Sunitinib VEGFR1, VEGFR2, PDGFR-,
c-Kit
Phase III
Vandetanib VEGF, EGFR Phase III
Cediranib VEGFR1, VEGFR2, VEGFR3 Phase II
Axitinib VEGFR1, VEGFR2, VEGFR3,
PDGFR-, c-Kit
Phase II
Motesanib VEGFR1, VEGFR2, VEGFR3,
PDGFR-, c-Kit
Phase I
Vatalanib VEGFR1, VEGFR2, VEGFR3,
PDGFR-, c-Kit
Phase III
Pazopanib VEGFR1, VEGFR2, VEGFR3,
PDGFR-, PDGFR-, c-Kit
Phase I
CP-547,632 VEGFR2, PDGF Phase II
BIBF 1120 VEGFR1, VEGFR2, VEGFR3,
PDGFR, FGFR
Phase II
XL647 EGFR, HER2, EphB4, VEGF Phase II
AEE788 EGFR, HER2, VEGF Phase I
KRN951 VEGFR1, VEGFR2, PDGFR,
c-Kit
Phase I
ABT-869 VEGF, PDGF Phase I
OSI-930 Kit, KDR Phase I
BMS-690514 pan HER, VEGF Phase I
Thalidomide BFGF Phase III
Lenalidomide BFGF Phase I
Pomalidomide BFGF Phase I
Cilengitide v3, v5 Phase I
TNP-470 Methionine aminopeptidase Phase I
AMG 386 Angiopoietin, Tie2 Phase I
DMXAA Vascular disrupting agent Phase II
VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor.
TABLE 2. Trials of Antiangiogenesis Agents Used as Monotherapy in Lung Cancer Trials
Drug Name Cell-Type Number Response (CR/PR) Disease Control Rate (CR/PR/SD) PFS
Aflibercept55 Non-squamous NSCLC 33 2 Not reported Not reported
Sorafenib59,60 NSCLC 54 0 59% 11.9 wk
NSCLC 6 2/5 Evaluable 4/5 Not reported
Sunitinib69,70 NSCLC 47 2% 19% 12.1 wk
NSCLC 63 9.5% 50.5% Not reported
Vandetanib71,73 NSCLC 83 Not reported 45% 11.0 wk
NSCLC 73 7% Not reported Not reported
Axitinib79 NSCLC 32 9.4% Not reported 5.8 mo
Vatalanib82 NSCLC 54 (qd) 2% 35% 2.4 mo
58 (bid) 7% 39% 3.7 mo
BIBF 112086 NSCLC 73 0 48% 1.6 mo
CR, complete response; PR, partial response; SD, stable disease; PFS, progression free survival; NSCLC, non-small cell lung cancer; qd, once daily dosing; bid, twice daily
dosing.
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fusion protein that binds circulating VEGF-A and placen-
tal growth factor, preventing binding to the cell membrane
receptor. It is engineered by combining domains from
VEGFR-1 and VEGFR-2 with the Fc domain of human
IgG.54 In the first 33 evaluable patients of a phase II
monotherapy trial of advanced NSCLC patients previously
treated with at least two regimens, two partial responses
were observed and the drug was well tolerated.55 Dyspnea,
hypertension, and noncardiac chest pain were the most
frequently reported adverse events. A second-line phase III
trial studying docetaxel with or without VEGF-trap is
currently recruiting, and trials of chemotherapy with and
without VEGF-trap are planned for the first-line treatment
of NSCLC.
Small Molecules
Sorafenib
Sorafenib (Nexavar, BAY43–9006; Bayer Pharmaceu-
ticals Corporation, West Haven, CT) is an oral multitargeted
tyrosine kinase inhibitor (TKI) against B-RAF, C-RAF,
VEGFR-2, VEGFR-3, PDGFR-, and kit.56 Sorafenib has
phase III evidence in advanced renal cell carcinoma (RCC),57
and more recently has demonstrated improved OS versus
TABLE 3. Important Phase III Clinical Trials Currently in Progress
Title Population Treated Study Arms
Primary
Endpoint
ATLAS (NCT00257608) 1st-line maintenance after chemotherapy  bevacizumab in
advanced NSCLC
Bevacizumab  erlotinib vs.
bevacizumab  placebo
PFS
BeTa lung (NCT00130728) 2nd-line NSCLC after failure of first-line chemotherapy Erlotinib  placebo vs.
erlotinib  bevacizumab
OS
ECOG E1505
(NCT00324805)
Chemotherapy / bevacizumab in resected stage Ib–IIIa
NSCLC
Vinorelbine/Cisplatin vs.
Gemcitabine/Cisplatin vs.
Docetaxel/Cisplatin. All
arms with or without
bevacizumab
OS
VITAL (NCT00532155) 2nd-line NSCLC after failure of first-line chemotherapy Docetaxel  aflibercept vs.
docetaxel  placebo
OS
ESCAPE
(NCT00300885) (closed)
1st line chemotherapy-naïve advanced NSCLC Carboplatin/Paclitaxel/Sorafenib
vs. Carboplatin/Paclitaxel/
Placebo
OS
NCT00558636 1st line chemotherapy-naïve advanced NSCLC Carboplatin/Paclitaxel/Sorafenib
vs. Carboplatin/Paclitaxel/
Placebo
OS
NExUS (NCT00449033) 1st line chemotherapy-naïve advanced NSCLC Gemcitabine/Cisplatin/Sorafenib
vs. Gemcitabine/Cisplatin/
Placebo
PFS
The SUN program
(NCT00457392)
Advanced NSCLC after failure of at least one line of
chemotherapy
Erlotinib vs. Erlotinib 
sunitinib
OS
ZODIAK (NCT00312377) 2nd-line NSCLC after failure of first-line chemotherapy Docetaxel  vandetanib 100
mg vs. docetaxel 
placebo
PFS
ZEAL (NCT00418886) 2nd-line NSCLC after failure of first-line chemotherapy Pemetrexed  vandetanib 100
mg vs. pemetrexed 
placebo
PFS
ZEST (NCT00364351) Advanced NSCLC after failure of at least one line of
chemotherapy
Vandetanib 300 mg vs.
erlotinib
PFS
ZEPHYR (NCT00404924) Advanced NSCLC after failure of chemotherapy and
1st-line TKI
Vandetanib 300 mg vs. best
supportive care
OS
NCIC CTG BR.24
(NCT00245154)
1st line chemotherapy-naïve advanced NSCLC Carboplatin/Paclitaxel/Cediranib
vs. Carboplatin/Paclitaxel/
Placebo
PFS
NCT00460317 1st line chemotherapy-naïve advanced NSCLC Gemcitabine/Cisplatin/Motesanib
vs. Gemcitabine/Cisplatin/
Placebo
PFS
FRAGMATIC
(NCT00519805)
1st line chemotherapy in newly diagnosed NSCLC or SCLC Local best practice lung
cancer treatment with or
without daily dalteparin for
24 wk
OS
TILT (NCT00475098) Post resection of stage I–IIIa NSCLC Local practice postoperative
treatment vs. Local practice
plus 12 wk daily tinzaparin
OS
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer; PFS, progression free survival; OS, overall survival.
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placebo in advanced hepatocellular carcinoma.58 In NSCLC,
two phase II trials have investigated sorafenib monotherapy
in relapsed advanced disease.59,60 Tumor responses were
observed and the drug was well tolerated, with rash,
diarrhea, and fatigue the most commonly cited toxicities.
One patient died of hemoptysis within 30 days of com-
pleting treatment. Three phase III first-line trials are ran-
domizing patients to standard chemotherapy (carboplatin/
paclitaxel in two studies or gemcitabine/cisplatin in the
third [NExUS]) with sorafenib or placebo (Table 3). The
largest of these trials, the ESCAPE study, was stopped
after a planned interim analysis, when the independent data
monitoring committee concluded that the study would not
meet its primary end point of improved OS. Furthermore,
higher mortality was observed in patients with squamous
cell histology in the sorafenib arm.61,62 The other two trials
continue to accrue, although in the light of the ESCAPE
results the NExUS study has stopped enrolling patients
with squamous histology. It may be that further develop-
ment of sorafenib in combination with chemotherapy in
NSCLC will be halted after these disappointing results.
Sorafenib has also been tested in phase I trials in
combination with either gefitinib or erlotinib.63,64 These
combinations were well tolerated and in both studies each
drug could be given at the full monotherapy dose. The
combination of sorafenib and bevacizumab has demon-
strated efficacy in a phase I trial in advanced solid tumors,
where 7 of 38 patients had a partial response, but 10
patients experienced grade 3 or 4 hypertension.65 A phase
I trial is investigating this combination in NSCLC.
In SCLC, sorafenib is being tested as monotherapy in
patients with platinum-treated extensive stage disease, and
also in combination with topotecan in patients with relapsed
disease. No results are available.
Sunitinib
Sunitinib (Sutent, SU11248; Pfizer, New York, NY) is
also an orally available multitargeted TKI against VEGFR-1,
VEGFR-2, PDGFR, and c-kit.66 Like sorafenib, sunitinib
received initial approval for the treatment of advanced
RCC.67 Efficacy has also been demonstrated in the treatment
of imatinib-resistant gastrointestinal stromal tumors.68 Two
phase II trials have investigated sunitinib as monotherapy in
previously treated advanced NSCLC, given daily either con-
tinuously or in a 4 weeks on and 2 weeks off schedule.
Although few confirmed partial responses were observed (2%
and 9.5%, respectively), stable disease was achieved by 17%
and 41%.69,70 The SABRE-L phase II trial is investigating a
combination of antiangiogenesis agents, testing carboplatin/
paclitaxel/bevacizumab with or without sunitinib in previ-
ously untreated patients. In addition to SABRE-L, sunitinib is
also being investigated in combination with erlotinib, in
patients with bronchoalveolar carcinoma or never-smokers,
and in patients with NSCLC and brain metastases. A phase
III trial is investigating sunitinib versus placebo in NSCLC
patients who have progressive disease after treatment with
both chemotherapy and an EGFR inhibitor. Finally, in extensive
stage SCLC, a phase I/II trial of cisplatin/etoposide and
sunitinib is currently recruiting patients (NCT00453154)
and a second-line SCLC trial as monotherapy is planned
(NCT00620347).
Vandetanib
Vandetanib (Zactima, ZD6474; Astra-Zeneca, Maccles-
field, UK) is a small-molecule inhibitor of both VEGF and
EGFR. In a phase II trial of 168 pretreated NSCLC patients,
vandetanib was compared with gefitinib with crossover upon
progression. Improved PFS was observed in the vandetanib arm
(11 versus 8.1 weeks, p 0.025).71 A phase III trial comparing
vandetanib with erlotinib in the second-line or third-line
setting is now recruiting and another phase III trial is testing
vandetanib versus placebo in patients who have progressed
after both chemotherapy and an EGFR TKI.
In another phase II trial the addition of vandetanib to
docetaxel demonstrated prolongation of PFS over docetaxel
alone (18.7 versus 12 weeks, p  0.07).72 Two ongoing
second-line phase III trials, the ZODIAK and ZEAL studies,
are comparing docetaxel with or without vandetanib and
pemetrexed with or without vandetanib, respectively. How-
ever in a first-line randomized phase II trial comparing
vandetanib versus carboplatin/paclitaxel versus carboplatin/
FIGURE 2. Eastern Cooperative Oncology Group (ECOG)
4599 study of paclitaxel and carboplatin (PC) versus bevaci-
zumab, paclitaxel and carboplatin (BPC). Reprinted with per-
mission from the New England Journal of Medicine.30 Copy-
right 2006 Massachusetts Medical Society.
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paclitaxel/vandetanib, vandetanib monotherapy had little ac-
tivity and there was no significant difference in PFS (23
versus 24 weeks, p  0.098) or OS (p  0.59).73 In SCLC
vandetanib failed to show a survival benefit over placebo as
maintenance therapy in responding patients, although a trend
in favor of maintenance vandetanib was seen in limited stage
patients and in women.74
Cediranib
Cediranib (Recentin, AZD2171, Astra-Zeneca, Maccles-
field, UK) is an oral TKI targeting VEGFR-1, VEGFR-2, and
VEGFR-3, has been investigated in NSCLC by the National
Cancer Institute of Canada Clinical Trials Group. Phase I
trials evaluated AZD2171 with carboplatin/paclitaxel, and
also with gemcitabine/cisplatin.75,76 In both studies toxicities
were manageable and antitumor activity was observed, with
8/20 and 2/9 partial responses observed, respectively. A
randomized phase II trial of carboplatin/paclitaxel with
AZD2171 or placebo has completed accrual. An analysis of
the first 120 patients showed significant improvements in
both response rate and PFS; however, this trial will not
proceed to phase III in view of the increased death rate seen
in the cediranib arm. A decision concerning the development
of future trials of cediranib in combination with chemotherapy
will be made once the final analysis of the full 300 patient phase
II study is available. AZD2171 is being tested in combination
with gefitinib in patients with advanced solid tumors. Accrual is
ongoing, however, in an interim report the authors reported no
unexpected AZD2171 toxicities with two partial responses and
stable disease seen in 22 of 48 evaluable patients.77
Cediranib has been investigated as monotherapy in the
second-line treatment of recurrent SCLC (NCT00245063).
The trial has completed but no results are yet published.
Another phase I trial of cediranib as first-line treatment with
cisplatin/etoposide in extensive stage lung cancer (SCLC or
NSCLC) is planned (NCT00621361).
Axitinib
Axitinib (AG-013736, Pfizer) is an oral TKI that inhibits
all VEGF receptors, PDGFR-, and c-Kit. It is well tolerated.
Responses were seen in a phase I study in one patient with
adenoid cystic carcinoma and two patients with RCC.78 Axitinib
has been studied in a phase II trial in advanced NSCLC, showing
clinical activity and manageable toxicities.79
Motesanib Diphosphate
Motesanib diphosphate (AMG706, Amgen Inc.,
Thousand Oaks, CA) is another orally bioavailable small
molecule inhibiting VEGFR-1–3, PDGF, and c-Kit. It was
well-tolerated in single-agent phase I investigations.80 In
an open label nonrandomized phase Ib study motesanib
was combined with carboplatin/paclitaxel, or with the
anti-EGFR antibody, panitumumab, or with both chemo-
therapy and panitumumab, in advanced NSCLC.81 The
combinations tested were well tolerated and five patients
had a partial response, although there were no responses
among 16 patients treated without chemotherapy in the
motesanib/panitumumab alone arm. Motesanib is currently
being evaluated in a placebo controlled phase III study
with carboplatin/paclitaxel, and in another phase II trial
patients are being randomized to carboplatin/paclitaxel
with either bevacizumab or motesanib.
Vatalanib
Vatalanib (PTK787/ZK222584, Novartis International
AG, Basel, Switzerland) also inhibits VEGFR-1, VEGF-2,
VEGFR-3, PDGFR-, and c-Kit. It has demonstrated modest
efficacy as monotherapy in the second-line treatment of
advanced NSCLC with a response rate less than 10% and
median OS of 7 months.82 This agent is currently not going
forward in development.
Pazopanib
Pazopanib (GW786034, GlaxoSmithKline, Middlesex,
UK) inhibits VEGFR-1, VEGF-2, VEGFR-3, PDGFR-,
PDGFR-, and c-Kit.83 In phase II NSCLC trials, pazopanib
is being tested as monotherapy in the second-line or third-line
setting in advanced disease, and also as neo-adjuvant treat-
ment in a “window of opportunity” study before resection of
stage I tumors.
CP-547,632
CP-547,632 (Pfizer) is an inhibitor of VEGFR-2 and
PDGF.84 It has been studied in a phase I/II trial in combina-
tion with carboplatin/paclitaxel as first-line therapy in
NSCLC. Dose limiting toxicities were diarrhea and rash, and
CP-547,632 did not seem to add to the efficacy of chemo-
therapy.85
BIBF 1120
BIBF 1120 (Boehringer Ingelheim, Ingelheim, Ger-
many) is a potent inhibitor of VEGF receptors, PDGFR,
and FGFR that has been investigated in a randomized
phase II trial as second-line or third-line treatment of
NSCLC.86 Of 73 treated patients, there were no objective
responses but stable disease was observed in 48%, rising to
59% in patients of performance status 0 or 1. A further
phase I trial has now established the maximum tolerated
dose of BIBF 1120 to be 200 mg twice daily in combina-
tion with carboplatin/paclitaxel.87
XL647
XL647 (Exelixis Inc.; South San Francisco, CA) is an
oral multikinase inhibitor with activity against EGFR, HER2,
EphB4, and VEGFR-2. In phase I trials one patient with
NSCLC had a partial response, and final results are await-
ed.88,89 Patients with either EGFR mutation or clinically
favorable characteristics (Asian ethnicity, female sex, never-
smokers) have entered a first-line phase II trial with single-
agent XL647 and accrual continues.90 A randomized trial
comparing XL647 to supportive care alone is in development.
AEE788
AEE788 (Novartis International AG), another multitar-
geted TKI, inhibits EGFR, HER2, and VEGFR-2. It has been
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investigated in phase I trials including patients with NSCLC
although efficacy data are not available.91,92
KRN951
KRN951 (Kirin Brewery Co. Ltd., Tokyo, Japan) in-
hibits phosphorylation of VEGFR1, VEGFR-2, PDGFR, and
c-Kit, and is being tested in an ongoing phase I dose-finding
study in the Netherlands.93,94
ABT-869
ABT-869 (Abbott Laboratories, Abbott Park, IL) is an
oral multitargeted TKI that inhibits VEGF receptors and
PDGF.95 No clinical data have yet been published, but on the
basis of provisional phase I data from leukemia and solid
tumor trials, a phase II study is now recruiting NSCLC
patients who have received at least one line of therapy in the
metastatic setting (NCT00517790).
OSI-930
OSI-930 (OSI Pharmaceuticals) is an oral multitargeted
TKI that inhibits Kit and kinase insert domain receptor.
Antitumor activity has been demonstrated in mouse xeno-
graft models,96 and this agent is now being investigated in
two phase I clinical trials in solid tumors, either as mono-
therapy (NCT00513851) or in combination with erlotinib
(NCT00603356). No results are available to date.
BMS-690514
BMS-690514 (Bristol Myers Squibb, New York, NY)
is another multitargeted TKI that inhibits all members of the
EGFR family and VEGF. Preclinical studies have demon-
strated activity in erlotinib-resistant NSCLC cell lines.97 This
agent is now being tested in phase I clinical trials both as
monotherapy and in combination with carboplatin/paclitaxel
(NCT00329004 and NCT00420186).
Thalidomide and Analogues
Thalidomide
Thalidomide (Celgene; Summit, NJ) is thought to exert
antiangiogenesis activity partially by antagonizing basic fi-
broblast growth factor (bFGF)-induced angiogenesis.98 It
showed limited efficacy in a small phase II NSCLC trial in
combination with first-line carboplatin/irinotecan.99 A simi-
larly designed phase II trial of thalidomide/carboplatin/irino-
tecan in untreated extensive stage SCLC was discontinued
after only six patients were enrolled due to poor tolerance of
thalidomide.100 Two London Lung Cancer Group phase III
trials of thalidomide in combination with standard chemo-
therapy, as first-line treatment of both NSCLC and SCLC,
were performed to confirm the phase II results. Unfortunately
neither demonstrated a survival benefit; futhermore, an in-
crease in thrombotic events was observed in patients receiv-
ing thalidomide.101,102 Thalidomide has also been investi-
gated in extensive-stage SCLC as maintenance therapy in
patients responding to chemotherapy. The initial phase II trial
demonstrated that this approach was well tolerated.103 How-
ever in the phase III trial, where patients responding after two
cycles of chemotherapy were randomized to receive four
more chemotherapy cycles plus thalidomide or placebo, there
was no significant improvement in survival.104
Lenalidomide
Lenalidomide (Revlimid, CC-5013, Celgene; Summit,
NJ) is a thalidomide analogue that is licensed for the treat-
ment of multiple myeloma and myelodysplastic syndrome. A
phase I study that investigated lenalidomide monotherapy
in 55 heavily pretreated patients with advanced solid
tumors demonstrated three radiologic responses.105 The
drug was well tolerated, although grade 3 or 4 neutropenia
was observed in four patients. A phase II trial in NSCLC
(NCT00179686) has completed accrual and results are
awaited.
Pomalidomide
Pomalidomide (Actimid, CC-4047, Celgene; Summit,
NJ), a third-generation thalidomide analogue, has been tested in
multiple myeloma106 and is being investigated in a phase I/IIa
study as maintenance therapy in extensive stage SCLC after
cisplatin/etoposide chemotherapy (NCT00537511).
Other Antiangiogenesis Inhibitors with
Different Mechanisms of Action
Cilengitide
Cilengitide (EMD 121974, Merck, Darmstadt, Ger-
many). During angiogenesis proliferating endothelial cells
interact with the extracellular matrix, a process that is medi-
ated by the endothelial transmembrane receptors, or integrins,
v3, and v5, which are up-regulated by VEGF and
bFGF. Phase I studies of cilengitide, which inhibits integrins,
have shown that the drug is well tolerated with no consistent
toxicities observed.107,108 No efficacy data are currently avail-
able in lung cancer.
TNP-470
TNP-470 (Takeda Chemical Industries Ltd., Osaka,
Japan) blocks angiogenesis by inhibiting methionine amino-
peptidase, an enzyme critical for endothelial cell prolifera-
tion. It has been studied in combination with paclitaxel in
NSCLC,109 and with carboplatin/paclitaxel in other solid
tumors.110 Reversible mild to moderate cognitive impairment
was observed, and further studies are planned.
AMG-386
AMG-386 (Amgen Inc.) is an intravenously adminis-
tered recombinant Fc-peptide fusion protein (peptibody) that
inhibits angiogenesis by preventing interaction between an-
giopoietins and Tie2 receptors. In a phase I trial in combina-
tion with chemotherapy in advanced solid tumors it was well
tolerated; however, there are only limited efficacy data.111
Phase II trials are ongoing, although none specifically in lung
cancer.
DMXAA
DMXAA (AS1404 or ASA404, Antisoma, London,
UK) is a small molecule vascular disrupting agent that has
been studied in a phase Ib/II and a subsequent phase II
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NSCLC trial in combination with carboplatin/paclitaxel. The
authors reported no significant added toxicity and a 50%
partial response rate.112,113 A phase III randomized study of
carboplatin/paclitaxel with AS1404 or placebo is planned.
Interferon
The interferons have antiangiogenic properties, partly
by bFGF blockade exerting antimigratory effects on endothe-
lial cells.114 Interferon- and interferon- were investigated
in the 1990s as maintenance therapy in patients with limited
or extensive stage SCLC after chemotherapy. In a series of
randomized trials, there was no observed survival benefit and
increased toxicity for those receiving interferon.115–118 In
NSCLC interferon- failed to add to the efficacy of radiation
in locally advanced disease in a single Radiation Therapy
Oncology phase III study.119
Other antiangiogenesis drugs that have failed to
progress through the development cycle, either because of
inactivity or toxicity, include SU5416, SU6668, and ZD6126.
Anticoagulation
Both malignancy and the treatment of malignancy are
independent risk factors for venous thromboembolism. In
vivo and in vitro experiments have demonstrated antiangio-
genic effects of both coumadin and heparin.120 In SCLC the
addition of heparin to standard chemotherapy has demon-
strated improved response rates and survival.121,122 The
FRAGMATIC trial is a large phase III trial aiming to recruit
2200 patients with either NSCLC or SCLC, randomized to
standard treatment with or without 24 weeks of daily dalte-
parin injections. The primary end point is OS. The trial is
recruiting patients, but results will probably not be available
before 2012. Finally, the French Tinzaparin in Lung Tumors
(TILT) study is a phase III randomized trial in patients with
resected NSCLC, who receive 12 weeks of daily tinzaparin.
Study completion is not expected until 2014.
DISCUSSION
Bevacizumab remains the only antiangiogenesis drug
with phase III level evidence in NSCLC. Although this is an
important advance in the treatment of NSCLC, there remain
a number of questions concerning the results of this trial.
Patients with squamous cell carcinoma, therapeutic anticoag-
ulation, or a history of brain metastases were excluded—
representing a considerable proportion of NSCLC patients
seen in routine lung cancer practice. Also the control arm
seemed to perform poorly, with a response rate of only 10%.
Furthermore, although full results are not yet reported, the
AVAil study has now announced no significant OS benefit in
the cohort of patients receiving bevacizumab. Although there
seems to be some benefit from adding bevacizumab by virtue
of improved PFS and response rates, the lack of OS benefit in
the AVAil study is disappointing. Given the modest added
toxicity, modest survival benefit in E4599 but not AVAiL,
and the current high cost of bevacizumab, many clinicians
and healthcare providers may reconsider the role of bevaci-
zumab. The benefit in E4599 was only seen in men, although
in a preplanned subgroup analysis of the AVAiL study there
was no difference by gender,35 and Hurwitz et al.28 reported
no effect of gender on outcome in their seminal study of
chemotherapy and bevacizumab in metastatic colorectal
cancer. Of interest, the small phase II vandetanib trials have
shown the reverse with a suggestion of greater benefit in
women than men. Sex is therefore a variable to watch closely
in upcoming phase III trials, and new trials should consider
including gender as a stratification factor.
Currently no predictive tests exist to guide the use of
antiangiogenesis drugs, and clinical practice is more dictated
by excluding patients in whom there is a perceived risk of
increased toxicity. These potentially include patients with
central or cavitating tumors, squamous histology, a history of
pretreatment hemoptysis or thromboembolic disease.
In the E4599 study, plasma VEGF levels were measured
before treatment but were not associated with survival.30 Serial
urinary levels of VEGF and bFGF did not correlate with
treatment response in a phase I trial of the oral TKI SU5416,
although four patients who responded to treatment had sig-
nificantly higher baseline urinary VEGF levels than 18 non-
responders.123 Mature circulating endothelial cells and circu-
lating endothelial progenitor cells, which are increased in
human cancers, express VEGFR-2 and are mobilized in
response to VEGF. Preclinical data suggest that they may act
as surrogate markers of response to antiangiogenic therapy,
but more work is required to confirm this.124,125
Functional single nucleotide polymorphisms of the
VEGF gene have been reported, with the variant allele of the
936CT and 405GC single nucleotide polymorphisms
associated with lower plasma VEGF levels.126–129 Recently
these polymorphisms have been shown to predict survival
in patients with resected stage I and II NSCLC,130 although
no other studies have been reported yet to validate these
findings.
Antiangiogenic drugs are often considered cytostatic
rather than cytotoxic, and in many cases tumor response is
associated with cavitation rather than shrinkage. However,
even extensive cavitation in the absence of shrinkage may
not be defined as a response using the Response Evaluation
Criteria in Solid Tumors.131 Therefore finding surrogate
markers of tumor response may be advantageous.
Hypertension seems to be a class effect associated with
almost all of the antiangiogenesis agents including monoclo-
nal antibodies and TKIs.132 E4599 reported a 7% rate of grade
3 or 4 hypertension for patients in the bevacizumab arm. In a
phase III colorectal cancer study, grade 3 or 4 hypertension
was reported in 11%,28 and in phase III advanced breast
cancer trials grade 3 or 4 hypertension was recorded in
14.8% and 17.9%.133,134 Trials of TKIs in NSCLC also
report hypertension as a common toxicity,59,60,69,70,73,75–77
but it is generally manageable with simple antihyperten-
sive management, and hypertension treatment algorithms
are now included in many clinical trials of these agents so
that treatment can be continued. It will be important to
monitor the outcome of the ECOG 1505 adjuvant bevaci-
zumab trial in NSCLC, in addition to adjuvant trials in
other malignancies, to determine whether longer exposure
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to these agents in patients who potentially are cured may
result in undetermined longer-term risks.
CONCLUSIONS
Currently E4599 remains the only randomized phase III
study demonstrating an OS benefit from antiangiogenesis
therapy in NSCLC (nonsquamous histology). Encouraging
efficacy data have been shown in several phase II trials with
a variety of novel antiangiogenesis agents, either as mono-
therapy or in combination with standard treatment. A number
of phase III trials are currently recruiting patients, and the
results of these are eagerly awaited. It is hoped that correla-
tive studies of markers of angiogenesis, performed using
tissues from the tumor banks associated with these trials, will
help to define the important predictive markers for this form
of treatment.
REFERENCES
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.
CA Cancer J Clin 2005;55:74–108.
2. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of
paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the
treatment of patients with advanced non–small-cell lung cancer: a
Southwest Oncology Group trial. J Clin Oncol 2001;19:3210–3218.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four
chemotherapy regimens for advanced non-small-cell lung cancer.
N Engl J Med 2002;346:92–98.
4. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer
Biol 1992;3:65–71.
5. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A. The history of
the angiogenic switch concept. Leukemia 2007;21:44–52.
6. Rosen LS. VEGF-targeted therapy: therapeutic potential and recent
advances. Oncologist 2005;10:382–391.
7. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its
receptors. Nat Med 2003;9:669–676.
8. Sun S, Schiller JH. Angiogenesis inhibitors in the treatment of lung
cancer. Crit Rev Oncol Hematol 2007;62:93–104.
9. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of
the HIF system. Nat Med 2003;9:677–684.
10. Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth
factor induction of the angiogenic phenotype requires Ras activation.
J Biol Chem 2001;276:49289–49298.
11. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth
factor expression in stage I non-small cell lung cancer correlates with
neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001;8:72–79.
12. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K.
Vascular endothelial growth factor expression in non-small-cell lung
cancer: prognostic significance in squamous cell carcinoma. J Thorac
Cardiovasc Surg 1998;115:1007–1014.
13. Ludovini V, Gregorc V, Pistola L, et al. Vascular endothelial growth
factor, p53, Rb, Bcl-2 expression and response to chemotherapy in
advanced non-small cell lung cancer. Lung Cancer 2004;46:77–85.
14. Nakashima T, Huang CL, Liu D, et al. Expression of vascular endo-
thelial growth factor-A and vascular endothelial growth factor-C as
prognostic factors for non-small cell lung cancer. Med Sci Monit
2004;10:BR157-BR165.
15. Niklinska W, Burzykowski T, Chyczewski L, Niklin´ski J. Expression
of vascular endothelial growth factor (VEGF) in non-small cell lung
cancer (NSCLC): association with p53 gene mutation and prognosis.
Lung Cancer 2001;34(Suppl 2):S59–S64.
16. Stefanou D, Goussia AC, Arkoumani E, Agnantis NJ. Expression of
vascular endothelial growth factor and the adhesion molecule E-
cadherin in non-small cell lung cancer. Anticancer Res 2003;23:4715–
4720.
17. Tomita M, Matsuzaki Y, Shimizu T, Hara M, Ayabe T, Onitsuka T.
Vascular endothelial growth factor expression in pN2 non-small cell
lung cancer: lack of prognostic value. Respirology 2005;10:31–35.
18. Kajita T, Ohta Y, Kimura K, et al. The expression of vascular
endothelial growth factor C and its receptors in non-small cell lung
cancer. Br J Cancer 2001;85:255–260.
19. Mineo TC, Ambrogi V, Baldi A, et al. Prognostic impact of VEGF,
CD31, CD34, and CD105 expression and tumour vessel invasion after
radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol
2004;57:591–597.
20. Seto T, Higashiyama M, Funai H, et al. Prognostic value of expression
of vascular endothelial growth factor and its flt-1 and KDR receptors in
stage I non-small-cell lung cancer. Lung Cancer 2006;53:91–96.
21. Yuan A, Yu CJ, Chen WJ, et al. Correlation of total VEGF mRNA
and protein expression with histologic type, tumor angiogenesis,
patient survival and timing of relapse in non-small-cell lung cancer.
Int J Cancer 2000;89:475–483.
22. Kim SJ, Rabbani ZN, Dewhirst MW, et al. Expression of HIF-1alpha,
CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung
cancer. Lung Cancer 2005;49:325–335.
23. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA.
Relation of neovascularisation to metastasis of non-small-cell lung
cancer. Lancet 1992;340:145–146.
24. Meert AP, Paesmans M, Martin B, et al. The role of microvessel
density on the survival of patients with lung cancer: a systematic
review of the literature with meta-analysis. Br J Cancer 2002;87:694–
701.
25. Dowell JE, Amirkhan RH, Lai WS, Frawley WH, Minna JD. Survival
in small cell lung cancer is independent of tumor expression of VEGF
and COX-2. Anticancer Res 2004;24:2367–2373.
26. Lucchi M, Mussi A, Fontanini G, Faviana P, Ribechini A, Angeletti
CA. Small cell lung carcinoma (SCLC): the angiogenic phenomenon.
Eur J Cardiothorac Surg 2002;21:1105–1110.
27. Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment
serum level of vascular endothelial growth factor (VEGF) is associated
with poor outcome in small-cell lung cancer. Int J Cancer 1998;79:
144–146.
28. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus
irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
N Engl J Med 2004;350:2335–2342.
29. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase
II trial comparing bevacizumab plus carboplatin and paclitaxel with
carboplatin and paclitaxel alone in previously untreated locally ad-
vanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;
22:2184–2191.
30. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or
with bevacizumab for non-small-cell lung cancer. N Engl J Med
2006;355:2542–2550.
31. Brahmer JR, Gray R, Schiller JH, Perry M, Sandler A, Johnson D.
ECOG 4599 phase III trial of carboplatin and paclitaxel bevaci-
zumab: subset analysis of survival by gender. J Clin Oncol 2006;24:
Abstract 7036.
32. Sandler AB, Johnson DH, Brahmer J, et al. Retrospective study of
clinical and radiographic risk factors associated with early onset, severe
pulmonary hemorrhage in bevacizumab-treated patients with advanced
non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24:Abstract
7068.
33. Sandler A. Bevacizumab in non small cell lung cancer. Clin Cancer
Res 2007;13:S4613–S4616.
34. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval
summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as
first-line treatment of advanced/metastatic recurrent nonsquamous non-
small cell lung cancer. Oncologist 2007;12:713–718.
35. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind
multicentre phase III study of bevacizumab in combination with cis-
platin and gemcitabine in chemotherapy-naı¨ve patients with advanced
or recurrent non-squamous non-small cell lung cancer (NSCLC):
BO17704. J Clin Oncol 2007;25:LBA7514.
36. Genentech. Genentech Provides Update on “AVAiL” Phase III Study of
Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous,
Non-Small Cell Lung Cancer. 2008. Available at: http://www.gene.
com/gene/news/press-releases/display.do?methoddetail&id
11207. Accessed August 20, 2008.
37. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitu-
mor activity of anti-epidermal growth factor receptor C225 monoclonal
Journal of Thoracic Oncology • Volume 3, Number 10, October 2008 Angiogenesis in the Treatment of Lung Cancer
Copyright © 2008 by the International Association for the Study of Lung Cancer 1181
antibody in combination with vascular endothelial growth factor anti-
sense oligonucleotide in human GEO colon cancer cells. Clin Cancer
Res 2000;6:3739–3747.
38. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination
anti-vascular endothelial growth factor receptor and anti-epidermal
growth factor receptor therapies on the growth of gastric cancer in a
nude mouse model. Eur J Cancer 2002;38:1133–1140.
39. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating
the anti-vascular endothelial growth factor monoclonal antibody bev-
acizumab in combination with the HER-1/epidermal growth factor
receptor tyrosine kinase inhibitor erlotinib for patients with recurrent
non-small-cell lung cancer. J Clin Oncol 2005;23:2544–2555.
40. Herbst RS, O’Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy
and safety of bevacizumab in combination with chemotherapy or
erlotinib compared with chemotherapy alone for treatment of recurrent
or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743–
4750.
41. Waples JM, Auerbach M, Boccia R, Wiggans RG, Steis R, Interna-
tional Oncology Network. A phase II study of oxaliplatin and pem-
etrexed plus bevacizumab in advanced non-squamous non-small cell
lung cancer. J Clin Oncol 2007;25:Abstract 18025.
42. Heist RS, Fidias P, Huberman M, Temel J, Sequist L, Lynch TJ. Phase
II trial of oxaliplatin, pemetrexed, and bevacizumab in previously-
treated advanced non-small cell lung cancer (NSCLC). J Clin Oncol
2007;25:Abstract 7700.
43. Reynolds C, Barrera D, Vu DQ, et al. An open-label, phase II trial of
nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin,
and bevacizumab in first-line patients with advanced non-squamous
non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25:Abstract
7610.
44. Patel JD, Hensing TA, Villafor V, Hart E, Bonomi P. Pemetrexed and
carboplatin plus bevacizumab for advanced non-squamous non-small
cell lung cancer (NSCLC): preliminary results. J Clin Oncol 2007;25:
Abstract 7601.
45. William WN, Kies MS, Fossella FV, et al. Phase II study of bevaci-
zumab in combination with docetaxel and carboplatin in patients with
metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2007;
25:Abstract 18098.
46. Kraut MJ. Phase II study of gemcitabine and carboplatin plus bevaci-
zumab for stage III/IV non-small cell lung cancer: preliminary safety
data. J Clin Oncol 2006;24:Abstract 17091.
47. Davila E, Lilenbaum R, Raez L, et al. Phase II trial of oxaliplatin and
gemcitabine with bevacizumab in first-line advanced non-small cell
lung cancer (NSCLC). J Clin Oncol 2006;24:Abstract 17009.
48. Ready N, Dudek AZ, Wang XF, Graziano S, Green MR, Vokes EE.
CALGB 30306: a phase II study of cisplatin (C), irinotecan (I) and
bevacizumab (B) for untreated extensive stage small cell lung cancer
(ES-SCLC). J Clin Oncol 2007;25:Abstract 7563.
49. Sandler A, Szwaric S, Dowlati A, Moore DF, Schiller JH. A phase II
study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for
previously untreated extensive stage small cell lung cancer (SCLC)
(E3501): a trial of the Eastern Cooperative Oncology Group. J Clin
Oncol 2007;25:Abstract 7564.
50. Spigel DR, Hainsworth JD, Yardley DA, et al. Phase II trial of
irinotecan, carboplatin, and bevacizumab in patients with extensive-
stage small cell lung cancer. J Clin Oncol 2007;25:Abstract 18130.
51. Zubkus JD, Spigel DR, Greco FA, et al. Phase II trial of irinotecan,
carboplatin, and bevacizumab in patients with limited-stage small cell
lung cancer. J Clin Oncol 2007;25:Abstract18133.
52. Camidge DR, Eckhardt SG, Diab S, et al. A phase I dose-escalation
study of weekly IMC-1121B, a fully human anti-vascular endothelial
growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab),
in patients (pts) with advanced cancer. J Clin Oncol 2006;24:Abstract
3032.
53. Wu Y, Zhong Z, Huber J, et al. Anti-vascular endothelial growth factor
receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin
Cancer Res 2006;12:6573–6584.
54. Riely GJ, Miller VA. Vascular endothelial growth factor trap in non
small cell lung cancer. Clin Cancer Res 2007;13:S4623–S4627.
55. Massarelli E, Miller VA, Leighl NB, et al. Phase II study of the efficacy
and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2
weeks in patients (Pts) with platinum- and erlotinib- resistant adeno-
carcinoma of the lung (NSCLA). J Clin Oncol 2007;25:Abstract 7627.
56. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43–9006,
Nexavar((R))), a dual-action inhibitor that targets RAF/MEK/ERK
pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor
vasculature. Methods Enzymol 2005;407:597–612.
57. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced
clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–134.
58. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in
advanced hepatocellular carcinoma (HCC): results of a phase III
randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007;
25:LBA1.
59. Gatzemeier U, Blumenschein G, Fosella F, et al. Phase II trial of
single-agent sorafenib in patients with advanced non-small cell lung
carcinoma. J Clin Oncol 2006;24:Abstract 7002.
60. Liu B, Barrett T, Choyke P, et al. A phase II study of BAY 43–9006
(Sorafenib) in patients with relapsed non-small cell lung cancer
(NSCLC). J Clin Oncol 2006;24:Abstract 17119.
61. Scagliotti G, von Pawel J, Reck M, et al. Sorafenib plus carboplatin/
paclitaxel in chemonaive patients with stage IIIB-IV non-small cell
lung cancer: interim analysis (IA) results from the phase III, random-
ized, double-blind, placebo-controlled, ESCAPE (Evaluation of Sor-
afenib, Carboplatin And Paclitaxel Efficacy in NSCLC) trial. J Thorac
Oncol 2008;4:S97.
62. Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals I.
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in
Patients With Non-Small Cell Lung Cancer. 2008. Available at:
http://www.onyx-pharm.com/wt/page/pr_1203347093. Accessed August 20,
2008.
63. Adjei AA, Molina JR, Mandrekar SJ, et al. Phase I trial of sorafenib in
combination with gefitinib in patients with refractory or recurrent
non-small cell lung cancer. Clin Cancer Res 2007;13:2684–2691.
64. Duran I, Hotte SJ, Hirte H, et al. Phase I targeted combination trial of
sorafenib and erlotinib in patients with advanced solid tumors. Clin
Cancer Res 2007;13:4849–4857.
65. Azad NS, Annunziata C, Barrett T, et al. Dual targeting of vascular
endothelial growth factor (VEGF) with sorafenib and bevacizumab:
clinical and translational results. J Clin Oncol 2007;25:Abstract 3542.
66. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and
antitumor activity of SU11248, a novel oral multitarget tyrosine kinase
inhibitor, in patients with cancer. J Clin Oncol 2006;24:25–35.
67. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon
alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–
124.
68. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety
of sunitinib in patients with advanced gastrointestinal stromal tumour
after failure of imatinib: a randomised controlled trial. Lancet 2006;
368:1329–1338.
69. Brahmer JR, Govindan R, Novello S, et al. Efficacy and safety of
continuous daily sunitinib dosing in previously treated advanced non-
small cell lung cancer (NSCLC): results from a phase II study. J Clin
Oncol 2007;25:Abstract 7542.
70. Socinski MA, Novello S, Sanchez JM, et al. Efficacy and safety of
sunitinib in a multicenter phase II trial of previously treated, advanced
non-small cell lung cancer (NSCLC). Ann Oncol 2006;17:Abstract
729PB.
71. Natale R, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in
patients with advanced NSCLC: final results from a two-part, double-
blind, randomized phase II trial. J Clin Oncol 2006;24:Abstract 7000.
72. Heymach JV, Johnson BE, Prager D, et al. A phase II trial of ZD6474
plus docetaxel in patients with previously treated NSCLC: follow-up
results. J Clin Oncol 2006;24:Abstract 7016.
73. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II
study of vandetanib (VAN) alone or in combination with carboplatin
and paclitaxel (CP) as first-line treatment for advanced non-small cell
lung cancer (NSCLC). J Clin Oncol 2007;25:Abstract 7544.
74. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib
or placebo in small-cell lung cancer patients after complete or partial
response to induction chemotherapy with or without radiation therapy:
National Cancer Institute of Canada Clinical Trials Group Study BR.
20. J Clin Oncol 2007;25:4278–4284.
75. Laurie SA, Gauthier I, Arnold A, et al. A phase I and pharmacokinetic
Wheatley-Price and Shepherd Journal of Thoracic Oncology • Volume 3, Number 10, October 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer1182
study of daily oral cediranib (AZD2171), an inhibitor of vascular
endothelial growth factor tyrosine kinases, in combination with carbo-
platin and paclitaxel in patients with advanced non-small cell lung
cancer: a study of the National Cancer Institute of Canada Clinical
Trials Group. J Clin Oncol 2008;26:1871–1878.
76. Goss GD, Laurie S, Shepherd FA, et al. IND. 175: phase I study of
daily oral AZD2171, a vascular endothelial growth factor receptor
inhibitor (VEGFRI), in combination with gemcitabine and cisplatin
(G/C) in patients with advanced non-small cell lung cancer (ANSCLC):
a study of the NCIC Clinical Trials Group. J Clin Oncol 2007;25:
Abstract 7649.
77. Van Cruijsen H, Voest EE, Van Herpen CM, et al. Phase I evaluation
of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in
combination with gefitinib, in patients with advanced tumors. J Clin
Oncol 2006;24:Abstract 3017.
78. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangio-
genesis agent AG-013736 in patients with advanced solid tumors:
pharmacokinetic and clinical results. J Clin Oncol 2005;23:5474–5483.
79. Schiller JH, Larson T, Ou SI, et al. Efficacy and safety of axitinib
(AG-013736; AG) in patients (pts) with advanced non-small cell lung
cancer (NSCLC): a phase II trial. J Clin Oncol 2007;25:Abstract 7507.
80. Rosen LS, Kurzrock R, Mulay M, et al. Safety, pharmacokinetics, and
efficacy of AMG 706, an oral multikinase inhibitor, in patients with
advanced solid tumors. J Clin Oncol 2007;25:2369–2376.
81. Blumenschein G, Sandler A, O’Rourke T, et al. Safety and pharmaco-
kinetics (PK) of AMG 706 with carboplatin/paclitaxel (C/P) and/or
panitumumab for the treatment of patients with advanced non-small
cell lung cancer (NSCLC). J Thorac Oncol 2007;2:S469.
82. Gauler TC, Besse B, Meric JB, et al. Phase II open-label study to
investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally
administered once daily or twice daily at 1,250 mg as second-line
monotherapy in patients (pts) with stage IIIB/IV non-small cell lung
cancer (NSCLC). J Clin Oncol 2007;25:Abstract 7541.
83. Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine
kinase inhibitor. Curr Oncol Rep 2007;9:115–119.
84. Beebe JS, Jani JP, Knauth E, et al. Pharmacological characterization of
CP-547,632, a novel vascular endothelial growth factor receptor-2
tyrosine kinase inhibitor for cancer therapy. Cancer Res 2003;63:7301–
7309.
85. Cohen RB, Langer CJ, Simon GR, et al. A phase I/randomized phase
II, non-comparative, multicenter, open label trial of CP-547,632 in
combination with paclitaxel and carboplatin or paclitaxel and carbo-
platin alone as first-line treatment for advanced non-small cell lung
cancer (NSCLC). Cancer Chemother Pharmacol 2007;60:81–89.
86. Von Pawel J, Kaiser R, Eschbach C, et al. A double blind phase II study
of BIBF 1,120 in patients suffering from relapsed advanced non-small
cell lung cancer (NSCLC). J Clin Oncol 2007;25:Abstract 7635.
87. Camidge DR, Conkling P, Stephenson J, et al. A phase I open label
study of continuous oral treatment with BIBF 1120 together with
carboplatin and paclitaxel treated patients with non-small cell lung
cancer (NSCLC): P3–138. J Thorac Oncol 2007;2:S738.
88. Wakelee HA, Adjei AA, Halsey J, et al. A phase I dose-escalation and
pharmacokinetic (PK) study of a novel spectrum selective kinase
inhibitor, XL647, in patients with advanced solid malignancies (ASM).
J Clin Oncol 2006;24:Abstract 3044.
89. Wakelee HA, Molina JR, Fehling JM, Lensing JL, Sikic BI. A phase I
study with exploratory pharmacodynamic endpoints of XL647, a novel
spectrum selective kinase inhibitor, administered orally daily to pa-
tients (pts) with advanced solid malignancies. J Clin Oncol 2007;25:
Abstract 14044.
90. Rizvi N, Kris MG, Miller V, et al. A phase II study of XL647 in
non-small cell lung cancer (NSCLC) patients enriched for presence of
EGFR mutations. J Thorac Oncol 2007;2:S737.
91. Baselga J, Rojo F, Dumez H, et al. Phase I study of AEE788, a novel
multitargeted inhibitor of ErbB and VEGF receptor family tyrosine
kinases: a pharmacokinetic (PK)-pharmacodynamic (PD) study to iden-
tify the optimal therapeutic dose regimen. J Clin Oncol 2005;23:
Abstract 3028.
92. Martinelli E, Takimoto C, Van Oosterom A, et al. AEE788, a novel
multitargeted inhibitor of ErbB and VEGF receptor family tyrosine
kinases: preliminary phase 1 results. J Clin Oncol 2005;23:Abstract
3039.
93. Nakamura K, Taguchi E, Miura T, et al. KRN951, a highly potent
inhibitor of vascular endothelial growth factor receptor tyrosine ki-
nases, has antitumor activities and affects functional vascular proper-
ties. Cancer Res 2006;66:9134–9142.
94. Eskens FA, Planting A, Van Doorn L, et al. An open-label phase I dose
escalation study of KRN951, a tyrosine kinase inhibitor of vascular
endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off
schedule in patients with advanced solid tumors. J Clin Oncol 2006;
24:Abstract 2034.
95. Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869,
a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther
2006;5:995–1006.
96. Garton AJ, Crew AP, Franklin M, et al. OSI-930: a novel selective
inhibitor of Kit and kinase insert domain receptor tyrosine kinases with
antitumor activity in mouse xenograft models. Cancer Res 2006;66:
1015–1024.
97. de La Motte Rouge T, Galluzzi L, Olaussen KA, et al. A novel
epidermal growth factor receptor inhibitor promotes apoptosis in non-
small cell lung cancer cells resistant to erlotinib. Cancer Res 2007;67:
6253–6262.
98. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an
inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082–
4085.
99. Miller AA, Case D, Atkins JN, et al. Phase II study of carboplatin,
irinotecan, and thalidomide in patients with advanced non-small cell
lung cancer. J Thorac Oncol 2006;1:832–836.
100. Riedel RF, Crawford J, Dunphy F, Herndon JE II, Garstc J, Kelley MJ.
Phase II study of carboplatin, irinotecan, and thalidomide combination
in patients with extensive stage small-cell lung cancer. Lung Cancer
2006;54:431–432.
101. Lee S-M, Woll PJ, James LE, et al. A phase III randomised, double
blind, placebo controlled trial of etoposide/carboplatin with or without
thalidomide in advanced small cell lung cancer (SCLC). J Thorac
Oncol 2007;2:S306–S307.
102. Lee S-M, Woll PJ, Rudd RM, et al. A phase III randomised, double
blind, placebo controlled trial of gemcitabine/carboplatin with or with-
out thalidomide in advanced non-small cell lung cancer (NSCLC):
C1–03. J Thorac Oncol 2007;2:S359.
103. Dowlati A, Subbiah S, Cooney M, et al. Phase II trial of thalidomide as
maintenance therapy for extensive stage small cell lung cancer after
response to chemotherapy. Lung Cancer 2007;56:377–381.
104. Pujol JL, Breton JL, Gervais R, et al. Phase III double-blind, placebo-
controlled study of thalidomide in extensive-disease small-cell lung
cancer after response to chemotherapy: an intergroup study FNCLCC
cleo04 IFCT 00–01. J Clin Oncol 2007;25:3945–3951.
105. Sharma RA, Steward WP, Daines CA, Knight RD, O’Byme KJ,
Dalgleish AG. Toxicity profile of the immunomodulatory thalidomide
analogue, lenalidomide: phase I clinical trial of three dosing schedules
in patients with solid malignancies. Eur J Cancer 2006;42:2318–2325.
106. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immuno-
modulatory thalidomide analog, CC-4047, in relapsed or refractory
multiple myeloma. J Clin Oncol 2004;22:3269–3276.
107. Eskens FA, Dumez H, Hoekstra R, et al. Phase I and pharmacokinetic
study of continuous twice weekly intravenous administration of Cilen-
gitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3
and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer
2003;39:917–926.
108. Undevia SD, Janisch L, Stadler WM, Wittemer SM, Ratain MJ. A
phase I and pharmacokinetic study of continuous infusion EMD
121974 (EMD), an antiangiogenic v3 and v5 integrin antagonist,
in patients with advanced solid malignancy. J Clin Oncol 2006;24:
Abstract 3052.
109. Herbst RS, Madden TL, Tran HT, et al. Safety and pharmacokinetic
effects of TNP-470, an angiogenesis inhibitor, combined with pacli-
taxel in patients with solid tumors: evidence for activity in non-small-
cell lung cancer. J Clin Oncol 2002;20:4440–4447.
110. Tran HT, Blumenschein GR Jr, Lu C, et al. Clinical and pharmacoki-
netic study of TNP-470, an angiogenesis inhibitor, in combination with
paclitaxel and carboplatin in patients with solid tumors. Cancer Che-
mother Pharmacol 2004;54:308–314.
111. Mita AC, Wang D, Takimoto CH, et al. AMG 386, a selective
angiopoietin 1/2-neutralizing peptibody, in combination with chemo-
Journal of Thoracic Oncology • Volume 3, Number 10, October 2008 Angiogenesis in the Treatment of Lung Cancer
Copyright © 2008 by the International Association for the Study of Lung Cancer 1183
therapy in adult patients with advanced solid tumors. J Clin Oncol
2007;25:Abstract 14033.
112. McKeage M, Investigators A-SG. Phase Ib/II study of DMXAA com-
bined with carboplatin and paclitaxel in non-small cell lung cancer
(NSCLC). J Clin Oncol 2006;24:Abstract 7102.
113. McKeage M, von Pawel J. Phase II study of DMXAA (AS1404) 1800
mg/m2 combined with carboplatin and paclitaxel in non-small cell lung
cancer: P3–116. J Thorac Oncol 2007;2:S728.
114. Blackhall FH, Shepherd FA. Angiogenesis inhibitors in the treatment
of small cell and non-small cell lung cancer. Hematol Oncol Clin North
Am 2004;18:1121–1141, ix.
115. Jett JR, Maksymiuk AW, Su JQ, et al. Phase III trial of recombinant
interferon gamma in complete responders with small-cell lung cancer.
J Clin Oncol 1994;12:2321–2326.
116. Kelly K, Crowley JJ, Bunn PA Jr, et al. Role of recombinant interferon
alfa-2a maintenance in patients with limited-stage small-cell lung
cancer responding to concurrent chemoradiation: a Southwest Oncol-
ogy Group study. J Clin Oncol 1995;13:2924–2930.
117. Mattson K, Niiranen A, Pyrhonen S, et al. Natural interferon alfa as
maintenance therapy for small cell lung cancer. Eur J Cancer 1992;
28A:1387–1391.
118. van Zandwijk N, Groen HJ, Postmus PE, et al. Role of recombinant
interferon-gamma maintenance in responding patients with small cell
lung cancer. A randomised phase III study of the EORTC Lung Cancer
Cooperative Group. Eur J Cancer 1997;33:1759–1766.
119. Bradley JD, Scott CB, Paris KJ, et al. A phase III comparison of
radiation therapy with or without recombinant beta-interferon for
poor-risk patients with locally advanced non-small-cell lung cancer
(RTOG 93–04). Int J Radiat Oncol Biol Phys 2002;52:1173–1179.
120. Mousa SA. Anticoagulants in thrombosis and cancer: the missing link.
Expert Rev Anticancer Ther 2002;2:227–233.
121. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of
combination chemotherapy with and without low-molecular-weight
heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266–
1271.
122. Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin
treatment increases survival in small cell lung cancer. “Petites Cellules”
Group. Cancer 1994;74:38–45.
123. Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A.
Results of a Phase I dose-escalating study of the antiangiogenic agent,
SU5416, in patients with advanced malignancies. Clin Cancer Res
2002;8:2798–2805.
124. Beaudry P, Force J, Naumov GN, et al. Differential effects of vascular
endothelial growth factor receptor-2 inhibitor ZD6474 on circulating
endothelial progenitors and mature circulating endothelial cells: impli-
cations for use as a surrogate marker of antiangiogenic activity. Clin
Cancer Res 2005;11:3514–3522.
125. Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate
markers in antiangiogenesis clinical trials. Br J Cancer 2003;89:8–14.
126. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E.
A common 936 C/T mutation in the gene for vascular endothelial
growth factor is associated with vascular endothelial growth factor
plasma levels. J Vasc Res 2000;37:443–448.
127. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype
analysis of the polymorphic human vascular endothelial growth factor
gene promoter. Cancer Res 2003;63:812–816.
128. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of
polymorphisms within the vascular endothelial growth factor (VEGF)
gene: correlation with variation in VEGF protein production. Cytokine
2000;12:1232–1235.
129. Zhai R, Gong MN, Zhou W, et al. Genotypes and haplotypes of the
VEGF gene are associated with higher mortality and lower VEGF
plasma levels in patients with ARDS. Thorax 2007;62:718–722.
130. Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in
early-stage non-small-cell lung cancer. J Clin Oncol 2008;26:856–862.
131. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to
evaluate the response to treatment in solid tumors. European Organi-
zation for Research and Treatment of Cancer, National Cancer Institute
of the United States, National Cancer Institute of Canada. J Natl
Cancer Inst 2000;92:205–216.
132. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G. Angio-
genesis inhibitor therapies: focus on kidney toxicity and hyperten-
sion. Am J Kidney Dis 2007;50:203–218.
133. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus
paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:
2666–2676.
134. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of
capecitabine compared with bevacizumab plus capecitabine in patients
with previously treated metastatic breast cancer. J Clin Oncol 2005;
23:792–799.
Wheatley-Price and Shepherd Journal of Thoracic Oncology • Volume 3, Number 10, October 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer1184
